SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ICN Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Paul R who wrote (939)10/31/1998 8:34:00 AM
From: Clouseau  Respond to of 1029
 
Paul - You have probably noticed that estimates are all over the map...$0.43 $0.34 $0.25 and -$0.10 are all nums that have been advanced by one analyst or another. Beats me. But the stock seems to be stable anyhow.

Lancet article pub was good news; 43% sustained recovery rate in cotherapy, vs 19% Intron A mono.

Dave



To: Paul R who wrote (939)11/1/1998 8:10:00 PM
From: shust  Read Replies (1) | Respond to of 1029
 
I don't think the actual earnings number this quarter will have a big impact on the stock price unless it was something totally unexpected (positive or negative). I believe what they say going forward will have more of an impact. Nobody is going to get my shares.

shust


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News